Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso

Journal of Medical Virology

Volumn 79, Issue 7, 2007, Pages 873-879

  Simpore, J ^a,b,c   Pietra, V ^a   Pignatelli, S ^a   Karou, D ^a,b   Nadembega, W M C ^a,b   Ilboudo, D ^a,b   Ceccherini Silberstein, F ^c   Ghilat Avoid Belem, W N ^a   Bellocchi, M C ^d   Saleri, N ^e   Sanou, M J ^f   Ouedraogo, C M ^g   Nikiema, J B ^b   Colizzi, V ^c   Perno, C P ^c,d   Castelli, F ^e   Musumeci, S ^h  

^a Camille Medical Centre Ouagadougou and Solidarity Reception Centre of Ouagadougou   (Burkina Faso)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f Family Planning Service   (Burkina Faso)

^g District Sanitaire de Bogodogo ^*  (Burkina Faso)

^h UNIVERSITY OF SASSARI   (Italy)

Author keywords

Antiretroviral therapy; Burkina Faso; Drug resistance; HIV; Mother to child transmission; Nevirapine

Indexed keywords

ANTIRETROVIRUS AGENT; CHLOROQUINE; COTRIMOXAZOLE; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; ARTIFICIAL FEEDING; ARTIFICIAL MILK; BREAST FEEDING; CHILD; DRUG SUBSTITUTION; FEMALE; GENE MUTATION; GENE SEQUENCE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MIXED INFECTION; PREGNANT WOMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STRUCTURAL GENE; VERTICAL TRANSMISSION; VIRUS RECOMBINANT; VIRUS STRAIN;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BURKINA FASO; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 34249868763     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20913     Document Type: Article

References (35)

1. Adeothy-Koumakpai S, Monnykosso CN, D'almeida M, Houansou J, Batossi G, Hodonou I, Agossou R, Adeyanju I, Tested J, Portal JL. 2004. Prevention of HIV mother to child transmission in Cotonou: Child follow-up [Article in French]. Arch Pediatr 11:1425-1429.
2. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, To lard B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. 2001. Genotypic correlates of phenotypic resistance to efavirenz in patient viruses isolates from failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75:4999-5008.
3. Permanent secretariat of the CNLS_IST. 2005. Tallies strategic of fight against the HIV/AIDS and the infections sexually transmissible (CSLS), 2006-2010, Burkina Faso.
4. Coetzee D, Hilderbrand K, Boulle A, Drape B, Abdullah F, Goemaere E. 2005. Effectiveness of the first district-wide program for the prevention of mother-to-child transmission of HIV in South Africa. Bull World Health Organ 83:483.
5. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL. 1994. Reduction of maternal-infant standard transmission of human immunodeficiency virus 1 with zidovudine treatment. N Engl J Med 331:1173-1180.
6. De Muylder X. 1993. Caesarian sections in developing countries: Some considerations. Health Pol Plan 8:101-112.
7. European Collaborative Study. 1994. Vertical Caesarean section and risk of transmission of HIV-1 infection. Lancet 343:1464-1467.
8. European Union Presidency Statement - Prevention of the HIV/AIDS. 2001. www.europa-eu-un.org/articles/en/article_262_en.htm.
9. Fernandez RC, Araujo LC, Medina-Acosta E. 2005. Prevention of vertical HIV transmission in Campos dos Goytacazes, Rio de Janeiro, Brazil. Cad Saude Publica 21:1153-1159.
10. Ferris RG, Hazen RJ, Roberts GB, Clear MH, Chan JH, Romines KR, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Shorts SA, Weaver KL, Selleseth DW, Moniri KR, Boone LR. 2005. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 49: 4046-4051.
11. Frederiksen H, Berenstein D, Munch-Petersen B. 2004. Effect of valin 106 one structure-function relation of cytosolic human thymidine kinase. Kinetic properties and oligomerization pattern of nine substitution mutants of V106. Eur J Biochem 271:2248-2256.
12. Garcia R, Prieto F, Arenas C, Rincon J, Caicedo S, Rey G. 2005. Reduction of HIV mother-to-child transmission in Colombia, two years of experiment, 2003-2005. Biomedica 25:547-564.
13. Gregoire LJ, Auregan G, Van Renterghem H. 2000. Epidemic of the HIV/AIDS: Diagnoses and operational answers www.pnud.bf.
14. Hazen RJ, Harvey RJ, Clear St MH, Ferris RG, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Shorts SA, Romines KR, Chan JH, Boone LR. 2005. Anti-human immunodeficiency standard virus 1 activity of the non-nucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Chemother Agents 49:4465-4473.
15. Koblavi-Deme S, Maurice C, Yavo D, Sibailly TS, N'guessan K, Kamelan-Tano Y, Wiktor SZ, Roeis TH, Chorba T, Nkengasong JN. 2001. Sensitivity and specificity of human immunodeficiency virus rapid serologic assays and boil. J Clin Microbiol 39:1808-1812.
16. Landesman HS, Kalish AL, Burns ND, Minkoff H, Fox HE, Zorrilla C, Garcia P, Fowler MG, Mofenson L, Tuomala R. 1996. Obstetrical factors and the standard transmission of human immunodeficiency virus 1 from mother to child. N Engl J Med 334:1617-1623.
17. Malyuta R, Newell MI, Ostergren M, Thorne C, Zhilka N. 2006. Prevention of mother-to-child transmission of HIV infection: Ukraine experiment to date. Eur J Public Health 16:123-127.
18. Matida LH, da Silva MH, Tayra A, Succi RC, Gianna MC, Goncalves A, Carvalho HB, Hearst N. 2005. Prevention of mother-to-child transmission of HIV in Sao Paulo State, Brazil: Year update. AIDS 19:S37-S41.
19. McIntyre J. 2005. Prevention of mother-to-child transmission of HIV: Treatment options. Expert Rev Anti Repugnant Ther 3:971-980.
20. Meda N, Msellati P, Van de Perre P, Salamon R. 1997. Reduction of the transmission mother-child of the HIV in the developing countries: Strategies of intervention available, obstacles with their implementation and prospects. Books Health 7:115-125.
21. Ministry for the Health of Burkina Faso. 2003. Report/Ratio of the Workshop on the production of the estimates of the prevalence of the HIV and the cases of AIDS 2002 to Burkina Faso, KAYA, November 24-25, 2003
22. Ministry for the Health of Burkina Faso. 2006. Report/Ratio of monitoring sentinel of the HIV, year 2004,Ouagadougou.
23. Nadembega WMC, Giannella S III, Simpore J, Ceccherini-Silberstein F, Pietra V, Bertoli A III, Pignatelli S, Bellocchi MC, Nikiema JB, Cappelli G, Bere A, Colizzi V, CF Perno CP, Musumeci S. 2006. Characterization of Drug-resistance Mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol 78:1385-1391.
24. ONUAIDS. 2005. Follow-up of the declaration of engagement on the HIV/AIDS (Report/ratio UNGASS)-Burkina Faso, Ouagadougou.
25. ONUSIDA. 2004. Au Burkina Faso: Passation de service à la présidence du groupe thématique 2004 (http://www.lefaso.net/ article.php3?id_article=1280).
26. Ouedraogo-Traore R, Montavon C, Sanou T, Vidal N, Sangare L, Sanou I, Soudre R, Mboupe S, Delaporte E, Peeters M. 2003. CRF06-cpx is the predominant variable HIV-1 in patient AIDS from Ouagadougou, the capital city of Burkina Faso. AIDS 17:441-444.
27. Pignatelli S, Simpore J, Pietra V, Ouedraogo L, Conombo G, Saleri N, Pizzocolo C, De Iaco GD, Tall F, Ouiminga A, Carosi G, Castelli F. 2006. Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso. Trop Med Int Health 11:350-357.
28. Rouzioux C, Costagliola D, Burgard M, Blanche S, Mayaux MJ, Griscelli C, Valleron AJ. 1995. Estimated standard timing of mother-to-child human immunodeficiency virus 1 (HIV-1) transmission by uses of a Markov model. The HIV infection in newborn French Collaborative Study Group. Am J Epidemiol 142:1330-1337.
29. Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ. 1999. Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 2:154-166.
30. Simpore J, Ilboudo D, Karou D, Pietra V, Granato M, Esposito M, Santarelli R, Pignatelli S, Bere A, Angeloni A. 2006a. Prevalence of HIv-8 infections associated with HIV, HBV and HCV in pregnant women in Burkina Faso. J Med Sci 6:93-98.
31. Simpore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J, Pignatelli S, Pietra V, Musumeci S. 2006b. Seroprevalence and Co-infection of Toxoplasma gondii, HBV and HCV HIV-negative among HIV infected and pregnant women in Burkina Faso. J Med Virol 78:730-733.
32. Simpore J, Pietra V, Savadogo A, Pignatelli S, Nikiema JB, Nadembega WM, Yara J, Zoungrana N, Bakouan D, Colizzi V, Castelli F, Musumeci S. 2006c. Reduction of mother-to-child transmission of HIV at Camille Medical Center in Burkina Faso. J Med Virol 78:148-152.
33. UNDP. 2001. Report/ratio on the human development, fights against the HIV/AIDS, Burkina Faso.
34. Unicef-Statistiques. 2004. En bref: Burkina Faso http://www.unice-f.org/ french/infobycountry/burkinafaso_statistics.html
35. WHO. 2004. Prevention of the transmission mother-child of the HIV/ AIDS in Burkina Faso: an original contractual step.